Sagimet Biosciences (SGMT) director receives stock option grant for 39,567 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sagimet Biosciences Inc. director Paul W. Hoelscher received a grant of stock options covering 39,567 shares of Series A Common Stock. The options have an exercise price of $6.48 per share and expire on June 11, 2036.

The award was granted at no cost to him and is structured as compensation, not an open-market trade. The underlying 39,567 shares will vest in twelve equal monthly installments beginning on June 12, 2026, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hoelscher Paul W.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	39,567	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 39,567 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 39,567 shares Exercise price: $6.48 per share Shares after grant: 39,567 derivative shares +3 more

6 metrics

Option grant size 39,567 shares Stock Option (Right to Buy) underlying Series A Common Stock

Exercise price $6.48 per share Conversion or exercise price of stock option

Shares after grant 39,567 derivative shares Total stock options following transaction

Transaction date June 12, 2026 Grant date of stock option

Expiration date June 11, 2036 Option expiration for Stock Option (Right to Buy)

Vesting schedule 12 monthly installments Equal monthly vesting after June 12, 2026, subject to continued service

Key Terms

Stock Option (Right to Buy), Series A Common Stock, Grant, award, or other acquisition, vesting

4 terms

Stock Option (Right to Buy) financial

"Transaction security title is listed as "Stock Option (Right to Buy)"."

Series A Common Stock financial

"The underlying security title is described as "Series A Common Stock"."

Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.

Grant, award, or other acquisition financial

"The transaction code description states "Grant, award, or other acquisition"."

vesting financial

"The shares underlying this option shall vest and become exercisable over twelve monthly installments."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/15/2026 - 04:22 PM Accepted by SEC EDGAR 06/15/2026 - 04:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoelscher Paul W.

(Last)

(First)

(Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO

CALIFORNIA

94402

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$6.48	06/12/2026		A		39,567		⁽¹⁾	06/11/2036	Series A Common Stock	39,567	$0	39,567	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Sagimet Biosciences (SGMT) director Paul Hoelscher report on this Form 4?

Paul W. Hoelscher reported receiving a stock option grant for 39,567 shares of Sagimet Biosciences Series A Common Stock. The option was awarded at no cost and represents compensation rather than an open-market share purchase or sale.

How many Sagimet Biosciences (SGMT) shares are covered by the new stock option grant?

The new stock option grant covers 39,567 shares of Sagimet Biosciences Series A Common Stock. These shares are underlying the option and will become exercisable over time according to the vesting schedule described in the filing’s footnote.

What is the exercise price and expiration date of the Sagimet Biosciences (SGMT) option granted to Paul Hoelscher?

The stock option granted to Paul W. Hoelscher has an exercise price of $6.48 per share and expires on June 11, 2036. This means he can buy shares at $6.48 any time after vesting and before expiration.

How does the stock option granted to Sagimet Biosciences (SGMT) director Paul Hoelscher vest?

The option vests in twelve equal monthly installments following June 12, 2026. Each month, a portion of the 39,567 underlying shares becomes exercisable, provided Paul W. Hoelscher continues to serve on each applicable vesting date.

Did Sagimet Biosciences (SGMT) director Paul Hoelscher buy or sell shares in the market in this Form 4?

No open-market buy or sell occurred. The Form 4 reports a compensation-related stock option grant coded as a grant, award, or other acquisition, with a transaction price per share of $0.00 at grant and no sale transaction disclosed.